AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23022750 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 47
Study 20950914 — intervention group
Group type: EXPERIMENTAL
Intervention: Single suture technique
Number of subjects: 50
Study 20950914 — intervention group
Group type: COMPARATOR
Intervention: Multiple suture technique
Number of subjects: 50
Study 18039681 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down treatment (COBRA regimen: sulphasalazine 2 g daily, methotrexate 15 mg weekly, oral prednisolone starting at 60 mg daily, tapering to 7.5 mg over 6 weeks)
Number of subjects: 71
Study 18039681 — intervention group
Group type: COMPARATOR
Intervention: Step-up treatment (DMARD monotherapy)
Number of subjects: 71
Study 16413428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg ddAVP
Number of subjects: 10
Study 16413428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg ddAVP
Number of subjects: 10
Study 12762270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial patients
Number of subjects: 53859
Study 11216493 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing isoflavones (ISP+)
Number of subjects: 81
Study 11216493 — intervention group
Group type: COMPARATOR
Intervention: Soy protein with low isoflavone content (ISP‐)
Number of subjects: 81
Study 9328363 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rHuEPO (1,500 U intravenously three times a week for 26 weeks)
Number of subjects: 19
Study 9328363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rHuEPO plus nandrolone decanoate (100 mg intramuscularly weekly)
Number of subjects: 19
Study 9328363 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 19
Study 8405026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 0.1 mg/kg IV
Number of subjects: 25
Study 8405026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3533372 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (24 mg daily for 28 days)
Number of subjects: 38
Study 3533372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3533372 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 38
Study 31444820 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 implants
Number of subjects: 64
Study 31444820 — intervention group
Group type: COMPARATOR
Intervention: S2 implants
Number of subjects: 64
Study 30464694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary decompression (pbd) before article publication
Number of subjects: 1997
Study 30464694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary decompression (pbd) after article publication
Number of subjects: 1997
Study 30464694 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients seen preoperatively by a gastroenterologist
Number of subjects: 1997
Study 28690083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 163
Study 28690083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 26341121 — intervention group
Group type: EXPERIMENTAL
Intervention: High ApRot (>4.0°, n = 41)
Number of subjects: 82
Study 26341121 — intervention group
Group type: COMPARATOR
Intervention: Low ApRot (≤4.0°, n = 41)
Number of subjects: 82
Study 26341121 — intervention group
Group type: EXPERIMENTAL
Intervention: ApRot ≥ 6.0°
Number of subjects: 82
Study 23965696 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.25% bupivacaine (nerve block of the infrapatellar branch of the saphenous nerve)
Number of subjects: 68
Study 23965696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 20505016 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Competence (EC)
Number of subjects: 638
Study 18216523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy followed by axillary lymph node dissection (ALND) only if SLN was metastatic (SLN arm)
Number of subjects: 697
Study 18216523 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND arm)
Number of subjects: 697
Study 18216523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 697
Study 16313908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/Exercise
Number of subjects: 37
Study 16313908 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 37
Study 14708961 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0
Study 14708961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with other drugs (cefepime, glycopeptide, linezolid)
Number of subjects: 0
Study 10631626 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 0
Study 10631626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3166044 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation during local anesthesia
Number of subjects: 32
Study 3166044 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia without midazolam sedation
Number of subjects: 32
Study 30448787 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge survey on stroke
Number of subjects: 143
Study 30448787 — intervention group
Group type: COMPARATOR
Intervention: Family history of stroke
Number of subjects: 143
Study 30448787 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 143
Study 30448787 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors
Number of subjects: 143
Study 30448787 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of stroke symptoms
Number of subjects: 143
Study 30448787 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to suspected stroke
Number of subjects: 143
Study 28039082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hyperoxic cerebral reperfusion (measured as every 10%·hour of hyperoxic cerebral reperfusion)
Number of subjects: 310
Study 28039082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia prior to ischemia
Number of subjects: 310
Study 28039082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 310
Study 28039082 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of F2‐isoprostanes and isofurans at ICU admission
Number of subjects: 310
Study 28039082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic cerebral reperfusion
Number of subjects: 310
Study 28532659 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (Strategies To Enhance Practice for Healthy Eating)
Number of subjects: 1700
Study 28532659 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed group (Strategies To Enhance Practice for Healthy Eating)
Number of subjects: 1700
Study 24227728 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended color on one side matched the ignored color on the opposite side
Number of subjects: 0
Study 24227728 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended color on one side was different from the ignored color on the opposite side
Number of subjects: 0
Study 21872843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sets × 12 repetitions (REPS) of resistance training, 2 times per week, combined with aerobic training (cycle ergometry 6 times per week for 17±4 minutes and walking 5 times per week for 45 minutes)
Number of subjects: 295
Study 21872843 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × 15 repetitions (REPS) of resistance training, 2 times per week, combined with aerobic training (cycle ergometry 6 times per week for 17±4 minutes and walking 5 times per week for 45 minutes)
Number of subjects: 295
Study 19563201 — intervention group
Group type: EXPERIMENTAL
Intervention: New unified method of scalp acupuncture
Number of subjects: 0
Study 19563201 — intervention group
Group type: COMPARATOR
Intervention: Method with scalp projection areas
Number of subjects: 0
Study 19563201 — intervention group
Group type: COMPARATOR
Intervention: Method with standard treatment lines
Number of subjects: 0
Study 17805064 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan, carboplatin, and imatinib (600 mg/day); treatment cycles were 28 days.
Number of subjects: 68
Study 14675232 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 21
Study 14675232 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 11445751 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-def patients
Number of subjects: 29
Study 11445751 — intervention group
Group type: COMPARATOR
Intervention: Uninjured controls
Number of subjects: 29
Study 9507618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training of the cervical musculature
Number of subjects: 119
Study 9507618 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment regimen
Number of subjects: 119
Study 9507618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 119
Study 9507618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study 8589024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 300 mg/m2 and folinic acid at 200 mg/m2 daily for five days
Number of subjects: 14
Study 2102134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20
Study 2102134 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study 224691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 46
Study 31823525 — intervention group
Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 300 µg with high-fat meal
Number of subjects: 95
Study 31823525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 31075314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (6 months, thrice weekly)
Number of subjects: 0
Study 31075314 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus education
Number of subjects: 0
Study 27790726 — intervention group
Group type: COMPARATOR
Intervention: GP2015 (50 mg s.c. injection)
Number of subjects: 0
Study 27790726 — intervention group
Group type: COMPARATOR
Intervention: GP2015 via autoinjector (AI) (50 mg s.c. injection)
Number of subjects: 0
Study 27790726 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN (50 mg s.c. injection)
Number of subjects: 0
Study 27790726 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2015 via prefilled syringes (PFS) (50 mg s.c. injection)
Number of subjects: 0
Study 26448615 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole treatment (10 mg/day)
Number of subjects: 113
Study 26448615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 113
Study 23745980 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional brackets (CBs)
Number of subjects: 38
Study 23745980 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLBs)
Number of subjects: 38
Study 23745980 — intervention group
Group type: COMPARATOR
Intervention: Control (comparison between CB and SLB)
Number of subjects: 38
Study 21828950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 8
Study 21828950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg) in BOS (+) group (n = 4)
Number of subjects: 8
Study 21828950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg) in BOS (−) group (n = 4)
Number of subjects: 8
Study 19854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (2 g/d)
Number of subjects: 76
Study 19854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Menhaden oil (2 g/d)
Number of subjects: 76
Study 19854375 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 76
Study 19854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Menhaden oil
Number of subjects: 76
Study 19854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 76
Study 16723614 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary peritoneal drainage
Number of subjects: 117
Study 16723614 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy with bowel resection
Number of subjects: 117
Study 15566659 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg pamidronate (group A)
Number of subjects: 90
Study 15566659 — intervention group
Group type: COMPARATOR
Intervention: 90 mg pamidronate (group B)
Number of subjects: 90
Study 11378834 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dippers (n = 9)
Number of subjects: 16
Study 9217246 — intervention group
Group type: EXPERIMENTAL
Intervention: Virend (15% ointment)
Number of subjects: 45
Study 9217246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery bypass grafts
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery bypass grafts
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery bypass grafts in group 1
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery grafts in group 1
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery bypass grafts in group 2
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery grafts in group 2
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative mortality
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative myocardial infarcts
Number of subjects: 80
Study 7934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal wound infections
Number of subjects: 80
Study 2906474 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (0.75, 1.5, or 3 g daily)
Number of subjects: 66
Study 2906474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2906474 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (1.5 g and 3 g daily)
Number of subjects: 66
Study 30231801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% added sugar (AS) diet
Number of subjects: 33
Study 30231801 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% added sugar (AS) diet
Number of subjects: 33
Study 27266517 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Cymbopogon flexuosus, Thymus zygis and Rosmarinus officinalis)
Number of subjects: 46
Study 27266517 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 46
Study 25542304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 62
Study 25542304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22459101 — intervention group
Group type: COMPARATOR
Intervention: Tricompartmental knee arthroplasty (TKA)
Number of subjects: 347
Study 22459101 — intervention group
Group type: COMPARATOR
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 347
Study 22459101 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 347
Study 22459101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing (HR)
Number of subjects: 347
Study 22459101 — intervention group
Group type: COMPARATOR
Intervention: Knee arthroplasties (TKA and UKA)
Number of subjects: 347
Study 22459101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroplasties (THA and HR)
Number of subjects: 347
Study 22459101 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 347
Study 19789443 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin <70 g/L)
Number of subjects: 125
Study 19789443 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin <95 g/L)
Number of subjects: 125
Study 19789443 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 125
Study 19789443 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 125
Study 18609051 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid prescription (30-35 ml/kg body weight/day)
Number of subjects: 74
Study 18609051 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid prescription (maximum fluid intake of 1.5 L/day)
Number of subjects: 74
Study 12641302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extraction
Number of subjects: 0
Study 12641302 — intervention group
Group type: COMPARATOR
Intervention: Historical background and literature review
Number of subjects: 0
Study 11018580 — intervention group
Group type: EXPERIMENTAL
Intervention: Various strategies to enhance adherence in randomized controlled trials
Number of subjects: 0
Study 8987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal approach with bilateral sacrospinous vault suspension and paravaginal repair
Number of subjects: 88
Study 8987919 — intervention group
Group type: COMPARATOR
Intervention: Abdominal approach with colposacral suspension and paravaginal repair
Number of subjects: 88
Study 1455374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy with methylprednisolone 25‐30 mg/kg/day for 3 consecutive days combined with cyclophosphamide 0.4‐0.5 g/sq. m BSA on the 3rd day, repeated quarterly for 12 months (Group 1 and Group 2)
Number of subjects: 30
Study 1455374 — intervention group
Group type: COMPARATOR
Intervention: No pulse therapy (Group 3)
Number of subjects: 30
Study 6147843 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam 1 mg
Number of subjects: 12
Study 6147843 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrazepam 5 mg
Number of subjects: 12
Study 6147843 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 28557854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bodyweight, mobility, and free-weights training (CBT)
Number of subjects: 39
Study 28557854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight and mobility training (BMT)
Number of subjects: 39
Study 28557854 — intervention group
Group type: COMPARATOR
Intervention: Physical education class (CON)
Number of subjects: 39
Study 30509308 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine, risperidone, and paliperidone
Number of subjects: 111
Study 26405064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Number of subjects: 24
Study 26405064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25269124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (n = 32)
Number of subjects: 45
Study 25269124 — intervention group
Group type: COMPARATOR
Intervention: Present centered therapy (n = 13)
Number of subjects: 45
Study 22020317 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administered under fed conditions
Number of subjects: 55
Study 22020317 — intervention group
Group type: COMPARATOR
Intervention: S-1 administered under fasting conditions
Number of subjects: 55
Study 22020317 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 with PPI
Number of subjects: 55
Study 22020317 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 under fasting conditions
Number of subjects: 55
Study 22020317 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 under fed conditions
Number of subjects: 55
Study 19710195 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk group (3-5 portions of dairy products daily)
Number of subjects: 121
Study 19710195 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained habitual diet)
Number of subjects: 121
Study 17261227 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (≥ 28 g of walnuts per day)
Number of subjects: 87
Study 17261227 — intervention group
Group type: COMPARATOR
Intervention: Control diet (≥ 2 g of walnuts per day)
Number of subjects: 87
Study 15330755 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (1 g of L‐ascorbate, 400 IU of D,L‐alpha‐tocopherol acetate, 600 mg of alpha‐lipoic acid)
Number of subjects: 16
Study 15330755 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 16
Study 15330755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pooled placebo+antioxidant)
Number of subjects: 16
Study 11242480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (n=16)
Number of subjects: 29
Study 11242480 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=13)
Number of subjects: 29
Study 9554641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oral airway oscillation (frequency 8 Hz; I:E ratio 9:1)
Number of subjects: 14
Study 9554641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oral airway oscillation (frequency 14 Hz; I:E ratio 8:1)
Number of subjects: 14
Study 9554641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (frequency 3 Hz; I:E ratio 4:1)
Number of subjects: 14
Study 9554641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (frequency 16 Hz; I:E ratio 1:1, alternating with frequency 1.5 Hz, I:E ratio 6:1)
Number of subjects: 14
Study 9554641 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest physical therapy (CPT)
Number of subjects: 14
Study 8066514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical and psychosocial training program
Number of subjects: 293
Study 8066514 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 293
Study 3408634 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 10/170
Number of subjects: 12
Study 3408634 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 16/260
Number of subjects: 12
Study 3408634 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 31452148 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV stigma reduction intervention
Number of subjects: 239
Study 31452148 — intervention group
Group type: COMPARATOR
Intervention: breast cancer education
Number of subjects: 239